Naval Special Warfare (NSW) operators are exposed to a variety of extreme environmental conditions and intense physical demands. In addition to breathing high pressure gases at depth, prolonged cold water immersion and inadequate recovery from sustained physical exertion negatively impact individual and team performance. Biotechnologies that could mitigate the effects of cold as well as support physical recovery represent a significant unmet need for the NSW operational community. Oxytocin (OT) has a wide range of actions both locally in the brain and peripherally in the body including skeletal muscle. These peripheral effects can be mediated by classic ligand-receptor activation given the abundant expression of the oxytocin receptor in peripheral tissues, along with local expression of OT in peripheral tissues where it is likely to act in an autocrine manner. Exogenous OT via intranasal administration is FDA Investigational New Drug (IND)-approved and has been demonstrated as an easy and safe method to increase circulating OT concentrations that may augment actions on peripheral tissues.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cognitive performance assessment score change (code substitution)
Timeframe: Within 3 hours post-treatment
Cognitive performance assessment score change (code substitution)
Timeframe: Within 3 hours post-treatment
Cognitive performance assessment score change (reaction time)
Timeframe: Within 3 hours post-treatment
Cognitive performance assessment score change (reaction time)
Timeframe: Within 3 hours post-treatment
Oculometric assessment score change (saccades)
Timeframe: Within 3 hours post-treatment
Oculometric assessment score change (blink rate)
Timeframe: Within 3 hours post-treatment
Oculometric assessment score change (blink duration)
Timeframe: Within 3 hours post-treatment